From Screening to Specialist Review: The Path Forward After Abnormal Results

An abnormal screening result is a finding that needs further assessment; it is not, by itself, a diagnosis. The path forward is to understand what the result means, complete the recommended follow-up, and—when indicated—have a specialist review the findings and discuss next steps. This matters because screening can identify disease early, but it can also produce false positives and uncertainty: the U.S. Preventive Services Task Force (USPSTF) estimates that about 12% to 13% of people screened for colorectal cancer with stool-based tests may have a false-positive result over 10 years, depending on the test. Knowing how results are classified, how diagnostic follow-up works, and what specialist review adds can help patients move from a screening alert to an informed plan.

Abnormal Screening Results and Their Meaning

A screening test is used to look for signs of a condition in people who may not have symptoms. The National Cancer Institute defines a positive screening result as a finding that suggests a condition may be present and requires further testing to determine whether it is actually there. In practice, “abnormal” is a broad label: the result may be mildly outside a reference range, suspicious for disease, or technically inadequate and in need of repetition.

Screening results are not final diagnoses because tests are designed to identify people who may benefit from closer evaluation, rather than to confirm disease on their own. The meaning of a result depends on the test, the person’s age and risk factors, prior results, and the relevant clinical guidelines. A positive result should therefore trigger a clear follow-up plan—not an assumption that cancer or another disease is present.

Positive, abnormal, and indeterminate findings

A positive or abnormal result means that the screening test detected a finding that crosses its threshold for further assessment. An indeterminate result is less conclusive: the test may not provide enough information to classify the finding, so repeat testing or a different diagnostic method may be needed. For example, a screening mammogram may identify an area requiring additional views, while an abnormal cervical screening result may lead to repeat testing, HPV testing, or colposcopy depending on the result and clinical history.

False positives and false negatives

A false positive occurs when screening suggests a problem that diagnostic evaluation does not confirm; a false negative occurs when a test misses a condition that is present. These limitations are one reason screening results must be interpreted in context. The USPSTF’s colorectal cancer screening evidence review reports that, over 10 years of annual testing, estimated cumulative false-positive rates vary by test—for example, approximately 12% to 13% for commonly used stool-based tests. These figures describe a screening strategy across repeated rounds, not the chance that any one person with an abnormal result has cancer.

Follow-Up After an Abnormal Screening Result

Follow-up is the sequence of evaluation used to clarify an abnormal screening finding. Depending on the test, it may involve repeating the screen, obtaining diagnostic imaging, conducting a laboratory test, or taking a tissue sample. The National Cancer Institute distinguishes screening from diagnostic testing: diagnostic tests are used to investigate a suspected condition and determine whether it is present.

The appropriate next step is specific to the result and the person’s circumstances. A mild abnormality may call for surveillance at a defined interval; a more concerning finding may require prompt diagnostic testing. Patients can ask the ordering clinician what the result means, what action is recommended, when it should happen, and who is responsible for arranging it.

Diagnostic testing clarifies the finding

Diagnostic testing is a closer evaluation of a screening signal. For an abnormal mammogram, it may include diagnostic mammographic views, ultrasound, or—when warranted—a biopsy. After a positive stool-based colorectal cancer screening test, colonoscopy is generally needed to examine the colon and determine the cause of the result. A screening test alone cannot establish the diagnosis, and the diagnostic method should be selected according to the test type and clinical guidance.

Timing, communication, and continuity of care

Timely follow-up matters because an unresolved result can delay diagnosis or prolong uncertainty. A 2021 systematic review published in JAMA Network Open found that delays of 12 months or longer in follow-up after an abnormal breast cancer screen were associated with worse outcomes, including more advanced disease and higher mortality, compared with shorter follow-up. The review also emphasized that follow-up intervals and consequences vary by clinical situation, so patients should follow the timeframe given by their care team rather than applying a single interval to every abnormal result.

A practical approach is to keep a copy of the report, confirm that the ordering clinic has received it, and ask for the follow-up recommendation in writing. If an appointment or test has not been scheduled, contact the clinic to clarify the next step. These actions support continuity, especially when care involves multiple offices or specialists.

Specialist Review After Abnormal Screening Results

Specialist review is an assessment by a clinician with expertise relevant to the finding, such as a radiologist, gastroenterologist, gynecologist, dermatologist, or cardiologist. It can help interpret complex results, select appropriate diagnostic testing, and explain the range of possible outcomes. A referral does not mean that a serious disease has been confirmed; it means the finding warrants expertise or procedures beyond routine screening follow-up.

The specialist’s role is to connect the screening result with the person’s medical history, risk profile, prior tests, and preferences. The review may end with reassurance and routine monitoring, or it may identify a need for further testing or treatment. Patients should ask what question the referral is intended to answer and whether records or images need to be transferred before the appointment.

What a specialist review may include

A specialist may review the original report and images, compare them with prior studies, perform a focused examination, and recommend additional testing. In radiology, comparison with earlier images can help determine whether a finding is new or stable. In gastroenterology, a positive stool screening test may lead to colonoscopy, which can both identify abnormalities and allow removal of some polyps. In cervical care, colposcopy can examine the cervix more closely and guide biopsy when indicated.

Shared decisions and second opinions

Shared decision-making means that clinicians explain options and trade-offs while taking account of a patient’s values and circumstances. It is especially useful when several reasonable follow-up approaches exist or when testing carries burdens, risks, or uncertainty. A second opinion may be appropriate when a diagnosis is complex, recommendations differ, or a patient wants another expert to review the evidence. It should complement, not unnecessarily delay, time-sensitive evaluation.

Navigating Barriers and Reducing Follow-Up Gaps

The path from screening to specialist review can be disrupted by cost, transportation, language barriers, limited appointment availability, unclear instructions, or difficulty reaching the care team. These are system and access challenges—not evidence that a patient is at fault. The Centers for Disease Control and Prevention (CDC) identifies patient navigation as a strategy that can help people overcome barriers to cancer screening and follow-up through education, appointment coordination, and connections to support services.

Patient navigation and care coordination

Patient navigation is practical assistance that helps a person move through the healthcare system. A navigator may explain the next steps, arrange appointments, help obtain records, identify transportation or financial resources, and support communication between clinics. The National Cancer Institute’s research on patient navigation describes its use across the cancer care continuum, including screening, diagnostic resolution, and treatment. Patients can ask their clinic whether navigation, interpreter services, or a care coordinator is available.

Questions to bring to the appointment

A short list of questions can make a specialist visit more useful. Consider asking:

  • What exactly was abnormal, and how certain is the finding?
  • What follow-up test or procedure do you recommend, and why?
  • How soon should it happen, and what could happen if it is delayed?
  • Are there alternatives, risks, preparation steps, or costs to consider?
  • Who will contact me with results, and whom should I call if I do not hear back?

Conclusion: Turning an Abnormal Result Into a Clear Plan

An abnormal screening result is a signal for follow-up, not a diagnosis. Understanding the result, completing the recommended diagnostic evaluation, and using specialist review when appropriate can resolve uncertainty and guide care. Because false positives occur and follow-up delays can matter, clear communication and reliable care coordination are essential. Read the report, confirm the next step and its timing with the ordering clinician, and seek help from a navigator or care coordinator if access barriers arise.

Sources: National Cancer Institute, “Cancer Screening Overview,” https://www.cancer.gov/about-cancer/screening/patient-screening-overview; U.S. Preventive Services Task Force, “Colorectal Cancer: Screening,” https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening; JAMA Network Open, “Association of Time to Follow-up After Abnormal Breast Cancer Screening Results and Patient Outcomes,” 2021, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782475; Centers for Disease Control and Prevention, “Patient Navigation Services,” https://www.cdc.gov/cancer/care/; National Cancer Institute, “Patient Navigation in Cancer Care,” https://cancercontrol.cancer.gov/research-emphasis/supplement/patient-navigation